Clinical Impact of Pharmaceutical Consultations in Patients Treated for Chronic Obstructive Pulmonary Disease at Home

Centre Hospitalier Universitaire de Nīmes1 site in 1 country174 target enrollmentJanuary 18, 2019

ConditionsChronic Obstructive Pulmonary Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Chronic Obstructive Pulmonary Disease
Sponsor: Centre Hospitalier Universitaire de Nīmes
Enrollment: 174
Locations: 1
Primary Endpoint: Number of exacerbation events
Status: Completed
Last Updated: 4 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The implementation of pharmaceutical consultations in the city or at the hospital could modify the occurrence of exacerbations related to chronic obstructive pulmonary disease after return of the patient to his home.

Registry

clinicaltrials.gov

Start Date

January 18, 2019

End Date

October 21, 2021

Last Updated

4 months ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Centre Hospitalier Universitaire de Nīmes

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The patient has signed the consent form.
•The patient is affiliated to a health insurance programme
•The patient is at least 18 years old (≥).
•The patient is admitted to complete hospitalization (for patients in the "Hospital and Control" groups).
•The patient is diagnosed with stage 2 to 4 Chronic Obstructive Pulmonary Disease. The diagnosis as well as the stage of the disease are validated by a pulmonologist at the facility.
•The patient has one or more inhaler devices to treat Chronic Obstructive Pulmonary Disease.
•The patient returns to his / her home when discharged from hospital (for patients in the "Hospital and Control" groups).
•The patient is available for a follow-up of 12 months.

Exclusion Criteria

•The subject participates in another interventional study.
•The subject is in an exclusion period determined by a previous study.
•The patient is under safeguard of justice.
•The subject refuses to sign the consent.
•It is not possible to give the patient (or his/her trusted-person) informed information.

Outcomes

Primary Outcomes

Number of exacerbation events

Time Frame: Month 12

Exacerbation events will be defined as any episode of increased respiratory symptoms, especially dyspnea, cough and sputum production, and increased sputum purulence.